Lily Zou is President and CEO of Fosun Pharma USA, where she is responsible for building and growing Fosun Pharma’s US business. Fosun Pharma USA has R&D, regulatory, and commercialization capabilities, with a portfolio of pharmaceutical and in vitro diagnostic products in the US market. It also invests and incubates cutting-edge technologies and products via its incubator FUSION Bioventures. Lily is also Chairman of the Board and Chief Business Officer of Archimmune Therapeutics, a portfolio company of FUSION Bioventures, and board member of Nature’s Sunshine Products (NATR), NovelStar and Glycotest. Prior to Fosun Pharma, Lily was Executive Director, BD&L at Sandoz Inc., where she executed various deals and added over 30 products to Sandoz portfolio with aggregated annual sales of over $700M. Prior to Sandoz, Lily worked at top management consulting firm (Bain), large pharmas (Wyeth, Millennium), and smaller biotechs (ArQule, Coley Pharmaceutical Group) in various functions including BD&L, strategy, portfolio management and drug discovery. 

 

Lily holds a Ph.D. in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing University.